Atlas Trials

Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline

Clinical trial NCT00506415 · COMPLETED

Trial details

NCT number
NCT00506415
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Alzheimer Disease
Start date
2007-06-01
Primary completion
2011-05-01
Enrollment
1584

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.